{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-012893","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.057000+00:00","generated_at":"2026-06-25T19:52:59.965478+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months","bullets":["24 patients treated; no cases of rejection or intraocular inflammation reported.","Cohort 4 (impaired vision) averaged 7.6-letter gain in study eye at Month 12; 25% gained ≥15 letters.","Five Cohort 4 subjects with OpRegen delivered to most/all GA area had average 12.8-letter gain and outer retinal structure improvement.","Majority of AEs were mild (Cohort 4: 93%); most common ocular AEs related to surgical procedure (conjunctival hemorrhage, epiretinal membrane).","OpRegen developed under worldwide collaboration with Roche and Genentech; larger controlled study needed to confirm findings."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-012893","json":"https://secwatch.observer/filing/0001493152-22-012893.json","markdown":"https://secwatch.observer/filing/0001493152-22-012893.md","text":"https://secwatch.observer/filing/0001493152-22-012893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/0001493152-22-012893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:52:59.965478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}